Congenital malformations are major causes of disease and death during the first years of life and, most of the time, functional replacement of the missing or damaged organs remains an unmet clinical need. Particularly relevant for the treatment of congenital malformation would be to collect the stem cells at diagnosis, before birth, to be able to intervene during the gestation or in the neonatal period. Human AFSCs (amniotic fluid stem cells), which have characteristics intermediate between those of embryonic and adult stem cells, have been isolated. c-Kit+Lin− cells derived from amniotic fluid display a multilineage haemopoietic potential and they can be easily reprogrammed to a pluripotent status. Although, in the future, we hope to use cells derived from the amniotic fluid, we and others have proved recently that simple organs such as the trachea can be engineered using adult progenitors utilizing decellularized cadaveric matrices. A similar approach could be used in the future for more complex organs such as the muscles, intestines or lungs.
Skip Nav Destination
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article| May 22 2014
Engineering tissue for the fetus: stem cells and matrix signalling
Paolo De Coppi
Paolo De Coppi 1
*Surgery Unit, University College London, 30 Guilford Street, London WC1N 1EH, U.K.
Search for other works by this author on:
Biochem Soc Trans (2014) 42 (3): 631–635.
March 31 2014
Paolo De Coppi; Engineering tissue for the fetus: stem cells and matrix signalling. Biochem Soc Trans 1 June 2014; 42 (3): 631–635. doi: https://doi.org/10.1042/BST20140069
Download citation file:
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your InstitutionSign in via your Institution
Get Access To This Article
Buy This Article